Drugs / 251154
last change Aug 2012 re-read 2 minutes ago

251154

Vaccine

Investigated by
GlaxoSmithKline

Trials 1 · a red edge is where a trial was stopped

201020112012201320142015201620172018201920202021202220232024202520262027
PhaseRegistry idDatesIndicationSponsorStatusOutcome
Phase 2 NCT01110044 Apr 2010 → Aug 2012 Rotavirus infection GlaxoSmithKline Withdrawn No outcome recorded

Evidence & citations 3 cited values

Every value below carries the sentence it was read from. 1 source stands behind the page.

FieldValueCited text
Known as 251154 ClinicalTrials.gov intervention name — accepted as the source's own label NCT01110044
Modality Vaccine “The purpose of the study is to evaluate the safety and immunogenicity of a birth dose of GSK Biologicals' reduced-antigen-content tri-component pertussis (251154) vaccine...” NCT01110044
Route Intramuscular Intramuscular, single dose” NCT01110044